Pioneering Excellence in Integrated Drug Discovery
Jubilant Biosys offers a comprehensive, streamlined and integrated drug discovery process designed to achieve rapid milestones in the discovery of novel therapeutics. Our services under Integrated Drug Discovery span Target Validation (TV), Hit Identification (HI) to Lead Optimization (LO) and Pre-Clinical Candidate Selection (PCC) across multiple therapeutic areas including but not limited to oncology, CNS, metabolic disorders, pain & inflammation.
With well enabled capabilities in oncology, metabolic disorders, CNS, pain and inflammation Jubilant, as an integrated discovery service provider has rapidly emerged as a leading collaborator for biotechnology and pharmaceutical companies worldwide.
Jubilant’s expertise in discovery informatics, computational chemistry / molecular modelling, medicinal chemistry, structural biology, in-vitro pharmacology, DMPK, in-vivo pharmacology and toxicology span over 20 years of successful delivery in first in class and best in class targets.
We have expertise in multiple target classes including kinases/non-kinases, enzymes & non-enzymes, GPCRs, orphan receptors, transporters and others. We strive to leverage advanced technologies and expertise to foster speedy execution and deliver promising drug candidates.
Jubilant Biosys at a Glance
- 450+ discovery scientists at our Bengaluru R&D campus
- 100+ successful Integrated Drug Discovery programs delivered globally
- 20+ years of innovation in discovery and development
- Expertise across small molecules, biologics, and complex targets
Oncology
30+ Programs
Metabolic Disorder
15+ Programs
CNS
15+ Programs
Pain & Inflammation (P&I)
20+ Programs
Our Integrated Drug Discovery Workflow
Jubilant’s preclinical workflow integrates target identification, validation, screening, optimization, and development, ensuring smooth transitions across stages and maximum data reproducibility.
Target Validation
Our target discovery and validation group has a proven track record in identifying disease-relevant targets across diverse classes including kinases, GPCRs, enzymes, orphan receptors, and transporters.
Capabilities include:
- Comprehensive biochemical and genetic validation
- Disease-linked target selection using cellular and molecular assays
- 2–6 month validation cycles, ensuring efficient project advancement
Comprehensive and early target validation is essential in establishing a strong link between target manipulation and its effectiveness in treating the disease, which greatly enhances the likelihood of success in clinical trials. Once a target reaches a satisfactory level of validation and connection to the disease, the project progresses to the hit identification phase.
HIT Identification
Our hit identification services leverage computational and experimental screening to identify and confirm active compounds against validated targets.
Approaches include:
- CADD-based de novo design, virtual screening, and fragment-based drug discovery (FBDD)
- Molecular docking and dynamics simulations
- Medium-throughput screening and biophysics-based hit validation
- Crystallography-supported DMTA (Design–Make–Test–Analyze) cycles for hit refinement
Our integrated platform ensures faster progression from hits to leads with high-quality,
reproducible data for preclinical development.
A Customized Approach to Discovery Partnerships
Jubilant operates on a customized approach offering innovative solutions across the drug discovery value chain to the biotechnology and pharmaceutical industry. To suit each client’s requirements in the best possible manner, we offer flexibility through the following business models:
- Integrated Drug Discovery Programs
- Milestone and Hybrid Models
- Full Time Equivalent (FTE) based
- Fee For Service (FFS) based
Jubilant collaborates with the world’s leading pharmaceutical and biotech companies, academic institutions and research foundations. Innovative and rigorous science, excellence in execution, and absolute integrity, combined with flexible business models has enabled Jubilant to deliver valuable outcomes in a relatively short period of time. The hallmark of Jubilant’s collaborative model is the creation of value to partners.
Drug Development Services
Our Drug Development Services extend beyond discovery, supporting the transition of promising leads into preclinical and clinical development phases.
Jubilant’s integrated infrastructure and multidisciplinary teams ensure every compound is scientifically validated, optimized for developability, and compliant with global regulatory
standards.
Our development-focused capabilities include:
- Lead Optimization: Improving potency, selectivity, and pharmacokinetics
- Preclinical Development: Safety and efficacy profiling, bioanalysis, and DMPK support
- Formulation and Preformulation Studies: Stability, solubility, and bioavailability testing
- Analytical Development: Characterization and quantification using LC-MS/MS, HPLC, and NMR
- Toxicology and GLP Support: Ensuring IND readiness and regulatory compliance
By integrating discovery and development, Jubilant provides a single-partner solution that
accelerates your path from molecule to market.
Stages of Integrated Drug Discovery and Development
Our unified Discovery-to-Development framework ensures data continuity and scientific consistency across all critical stages:
- Target Validation – Establishing target-disease linkage
- Hit Identification – Discovering and confirming active molecules
- Lead Optimization – Refining properties for potency, selectivity, and PK
- Preclinical Candidate Selection – Selecting the most viable candidates
- Preclinical Development – Ensuring safety, stability, and formulation success
This fully integrated model improves efficiency, reduces rework, and increases the
probability of clinical success.
Integrated
Drug Discovery
Workflow
Integrated Drug Discovery (IDD) SolutionsOffered by Jubilant Biosys
Target to Lead Generation
- Protein production, Crystallography, SPR platform for screening
- Fragment identification and Screening
- Medicinal, Computational & Analytical Chemistry approaches
- In-vitro Screening and Profiling
- Early ADMET & PK
- In-vivo Pharmacology
Lead Optimisation
- Medicinal Chemistry
- DMPK
- SBDD (Co-crystallisation, Computational Modelling)
- Target Engagement & Disease Models, Safety Profile
- Pre-formulation
Candidate Selection (IND)
- Process Development (Including Flow Chemistry), Scale-up & GMP API Supply
- Genotox (Non-GLP & GLP Toxicology)
- D2M Predictions (WinNonlin)
API Custom Scale up
- GMP API scale- up to MT
- OEB Class 1-3 API Potency
Why Jubilant Biosys for Integrated Drug Discovery & Development?
As a trusted CRDMO partner, Jubilant Biosys brings together discovery, development, and manufacturing capabilities under one integrated framework.
Key Differentiators:
- 100+ IDD programs delivered successfully across major therapeutic areas.
- Preferred collaborator for biotech & pharma companies worldwide for the past two decades.
- 6:1 Masters-to-PhD scientist ratio with global research experience.
- Expertise across multiple target classes and modalities.
- De-novo assay development and in vivo model validation.
- Seamless DMPK, ADMET, and toxicology support.
- ISO 9001:2015, ISO 14001:2015, and ISO 45001:2018 certified facilities.
- End-to-end CRDMO capabilities extending beyond preclinical development.
Partner with Jubilant Biosys
Accelerate your next therapeutic program with Jubilant’s Integrated Drug Discovery and Development Services. Whether you require full-spectrum IDD support or modular engagement, our scientific experts deliver customized, results-driven solutions for your pipeline.
Contact us today to learn how our integrated approach, scientific excellence, and global
experience can help bring your next innovation to life.